Lexicon Pharmaceuticals, Inc.
$1.84
▼
-3.05%
2026-04-21 08:00:01
www.lexpharma.com
NCM: LXRX
Explore Lexicon Pharmaceuticals, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$764.74 M
Current Price
$1.84
52W High / Low
$1.95 / $0.49
Stock P/E
—
Book Value
$0.3
Dividend Yield
—
ROCE
-29.8%
ROE
-39.72%
Face Value
—
EPS
$-0.14
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
81
Beta
0.95
Debt / Equity
57.87
Current Ratio
4.88
Quick Ratio
4.87
Forward P/E
-8.27
Price / Sales
14.63
Enterprise Value
$694.74 M
EV / EBITDA
-14.39
EV / Revenue
13.95
Rating
None
Target Price
$3.36
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Ovid Therapeutics Inc. | $2.89 | — | $381.12 M | — | -29.75% | -17.51% | $3.1 / $0.27 | $1 |
| 2. | Keros Therapeutics, Inc. | $11.66 | 2.64 | $230.1 M | — | 21.27% | 19.9% | $22.55 / $10.41 | $15.51 |
| 3. | Cybin D/B/A Helus Pharma | $5.61 | — | $1.92 M | — | -60.35% | -55.89% | $12.7 / $5.9 | $5.49 |
| 4. | Cogent Biosciences, Inc. | $37 | — | $6.05 B | — | -38.16% | -73.7% | $43.73 / $4.12 | $3.4 |
| 5. | OmniAb, Inc. | $1.55 | — | $237.44 M | — | -24.23% | -23.36% | $2.29 / $1.22 | $1.85 |
| 6. | Coherus Oncology, Inc. | $1.99 | 1.76 | $295.28 M | — | -155.52% | -473.47% | $2.62 / $0.71 | $0.5 |
| 7. | Bio Green Med Solution, Inc. | $1.19 | — | $6.54 M | 0.93% | 552.16% | -1.28% | $100.8 / $0.73 | $1.27 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 5.49 M | 14.18 M | 28.87 M | 1.26 M | 26.55 M |
| Operating Profit | -14.78 M | -12.19 M | 3.74 M | -25.68 M | -32.74 M |
| Net Profit | -15.53 M | -12.77 M | 3.25 M | -25.3 M | -33.77 M |
| EPS in Rs | -0.04 | -0.03 | 0.01 | -0.06 | -0.08 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 49.8 M | 31.08 M | 1.2 M | 0.14 M |
| Operating Profit | -48.91 M | -197.12 M | -171.75 M | -100.76 M |
| Net Profit | -50.34 M | -200.4 M | -177.12 M | -101.94 M |
| EPS in Rs | -0.12 | -0.47 | -0.42 | -0.24 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 184.99 M | 298.42 M | 229.43 M | 194.3 M |
| Total Liabilities | 77.45 M | 152.47 M | 136.32 M | 77.17 M |
| Equity | 107.54 M | 145.95 M | 93.11 M | 117.12 M |
| Current Assets | 101.89 M | 246.19 M | 176.55 M | 140.87 M |
| Current Liabilities | 20.87 M | 45.25 M | 31.55 M | 23.17 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -67.85 M | -178.78 M | -161.9 M | -88.85 M |
| Investing CF | 113.02 M | -15.38 M | -49.94 M | -71.08 M |
| Financing CF | -48.5 M | 238.35 M | 187.96 M | 142.21 M |
| Free CF | -67.85 M | -179.81 M | -162.37 M | -90.18 M |
| Capex | — | -1.03 M | -0.47 M | -1.33 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 2481.48% | 766.19% | — | — |
| Earnings Growth % | -13.15% | -73.74% | — | — |
| Profit Margin % | -644.78% | -14710.88% | -73341.01% | — |
| Operating Margin % | -634.2% | -14264.95% | -72489.21% | — |
| Gross Margin % | 98.02% | 92.94% | 100% | — |
| EBITDA Margin % | -592.93% | -13576.74% | -71033.81% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.